ARCA Awarded Method Patent for Gene Response Testing with Investigational Heart Failure Drug | GenomeWeb

Originally published March 26.

By Turna Ray

ARCA has received a patent
from the US Patent and Trademark Office on genetic methods for identifying heart failure patients most likely to benefit from the investigational beta-blocker bucindolol.

Patent number 7,678,824, entitled "Methods for Treatment with Bucindolol Based on Genetic Targeting," provides market exclusivity to ARCA for its approach to treating patients with heart failure.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.